EMA/CO化疗方案治疗恶性滋养细胞肿瘤的临床疗效观察

目的:恶性滋养细胞肿瘤(Malignant trophoblastic tumor)是胚胎滋养细胞发生病变而产生的恶性肿瘤,严重威胁女性患者的身体健康及生活质量。本研究对EMA/CO(etoposide,methotrexate,actinomycin D,cyclophosphamide and vincristine)化疗方案治疗恶性滋养细胞肿瘤的临床效果及毒副反应情况进行探讨,旨在为该病的临床治疗积累经验。方法:选取我院2010年8月-2012年12月收治的恶性滋养细胞肿瘤患者58例,随机分为研究组和对照组,每组各29例。对照组采用5-Fu+KSM方案进行治疗,研究组采用EMA/CO方案治疗。观察并比较两组患者的治疗总有效率及毒副反应的发生情况。结果:对照组治疗总有效率为75.9%,研究组治疗总有效率为79.3%,两组患者的临床疗效无显著差异(P0.05)。研究组白细胞减少、呕吐及口腔溃疡程度均比对照组轻,差异具有统计学意义(P0.05)。结论:应用EMA/CO化疗方案治疗恶性滋养细胞肿瘤具有积极的作用,不但可以获得较好的近期疗效,且毒副反应较轻,值得临床应用推广。

Clinical Observation on the Efficacy of EMA/CO Regimen on the Treatment of Malignant Trophoblastic Tumor

Objective： Malignant trophoblastic tumor is a kind of cancer that brought by the pathological changes of embryonic nourish cells which would seriously influence the health and life of female patients. This article is written to discuss the clinical effects and adverse reactions that induced by the chemotherapy of EMA/CO on the treatment of malignant trophoblastic tumor so as to accumulate the experience for clinical treatment. Methods： 58 cases with malignant trophoblastic tumor who were treated in our hospital from August 2010 to December 2012 were selected and randomly divided into the study group and the control group with 29 in each one. The patients in the control group were treated by 5-Fu＋KSM, while the patients in the study group were given the EMA/CO. Then the rate of total efficacy and the incidence of adverse reactions of patients were observed and compared between the two groups. Results： The rate of total efficacy in the control group was 75.9% which was similar to the 79.3% in the study group with no significant difference（P〈0. 05）. There were statistically significant differences about the leukopenia reduction, the vomiting and the oral cavity ulcer of patients between the two groups（P〈0.05）. Conclusions： It is indicated that the application of EMA/CO on the treatment of malignant trophoblastic tumor should be well promoted to the clinical field with the advantages of better efficacy and lighter adverse reaction.